UK - Imperial Innovations leads £15m Circassia funding

Circassia provides allergy T-cell vaccines based on its proprietary ToleroMune technology. The results of the vaccines show that short treatment regimes can significantly reduce patients' symptoms, without the need for adjuvants or other immune stimulators, while proving well tolerated.

The funding will support the acceleration of the vaccine programme into late-stage development and advance the clinical development of the company's broader portfolio of novel allergy T-cell vaccines.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland